Experiments in rodents suggest that hypothalamic insulin signaling essentially contributes to the acute control of peripheral glucose homeostasis. Against this background, we investigated in healthy humans whether intranasal (IN) insulin, which is known to effectively reach the brain compartment, impacts systemic glucose metabolism. Twenty overnight-fasted healthy, normal-weight men were IN administered 210 and 420 IU (10 and 20 IU every 15 min) of the insulin analogue aspart (ins-asp) and placebo, respectively, during experimental sessions lasting 6 h. The use of ins-asp rather than human insulin enabled us to disentangle exogenous and endogenous insulin kinetics. IN insulin dose-dependently decreased plasma glucose concentrations while reducing C-peptide and attenuating endogenous insulin levels. However, we also observed a slight dose-dependent permeation of ins-asp into the circulation. In control experiments mimicking the systemic but not the central nervous uptake of the IN 210 IU dose via IV infusion of ins-asp at a dose of 0.12 mIU/kg/24h (n=10), we obtained essentially identical effects on fasting plasma glucose concentrations. This pattern indicates that sustained IN insulin administration to the human brain to enhance central nervous insulin signaling does not acutely alter systemic glucose homeostasis beyond effects accounted for by concurrent mild hyperinsulinemia.
Studies in rodents indicate that insulin controls systemic glucose metabolism not only via direct effects on peripheral organs, but also via a brain-liver axis governed by the hypothalamus (1) (2) (3) . Intracerebroventricular (ICV) infusion of insulin in rats induced a 44% reduction in hepatic glucose production within 4 hours of a peripheral insulin clamp, which could be blocked by ICV infusion of insulin antibodies (1). This effect is assumed to be mediated by the activation of hypothalamic ATP-sensitive potassium (K + ATP ) channels and vagal inputs to the liver (3). However, in dogs receiving carotid artery insulin infusions to raise cerebral insulin concentrations, a fourfold increase in head insulin during peripheral hyperinsulinemia did not enhance hepatic insulin sensitivity within 3 hours (4). Moreover, the impact of hepatic portal vein insulin delivery on hepatic glucose flux during a pancreatic clamp in the conscious dog was not altered by the inhibition of hypothalamic insulin action (5). Here we investigated whether central nervous insulin signaling contributes to the acute control of peripheral glucose homeostasis in humans. We made use of the intranasal (IN) route of insulin administration that directly targets the brain (6,7) and effectively modulates CNS functions including the regulation of energy balance (8, 9) , electroencephalographic brain activity (10) , and cognition (8, 11, 12) . We administered IN insulin aspart (ins-asp) that compared with regular insulin has an identical binding profile to the receptor (13) but a reduced tendency to form hexamers (14) , which increases its bioavailability and functional impact (12) while the mechanism of action of regular insulin is preserved. This enabled us to distinguish exogenous from endogenous insulin and to estimate the relative contributions of CNS and systemic insulin to the acute control of glucose homeostasis.
Research Design and Methods
Two double-blind, placebo-controlled, balanced within-subject experiments (I and II) which conformed to the declaration of Helsinki and were approved by the local ethics committee were conducted in healthy men (Table 1) 1 puff/nostril), two 0.1-ml puffs of ins-asp (420 IU condition) or two 0.1-ml puffs of placebo were given every 15 min. Subjects were monitored to ensure a constant state of vigilance, and blood was repeatedly sampled (see Figure 1 ).
In experiment I, IN ins-asp administration at both doses induced discernible increases in circulating ins-asp concentrations (see Results). Therefore, in experiment II we administered ins-asp intravenously (IV) to induce ins-asp plasma levels comparable to those found in the IN 210 IU condition of experiment I, albeit at a much lower degree of brain permeation than achieved by IN administration (6) . In a dose-finding experiment in 5 healthy men, we first determined the dose of IV ins-asp mimicking the increase in serum ins-asp observed in the 210 IU condition of experiment I. Subsequently, 10 male subjects (Table 1) were examined in two experimental conditions, IV ins-asp and placebo, whose set-up was identical to experiment I except that instead of IN administration, ins-asp compared to placebo (0.9% NaCl) was IV administered at a body weight-adjusted dose of 0.12 mIU/kg/24h from 0845-1345 h.
Analyses of plasma glucose and hormonal parameters. Blood samples were centrifuged and supernatants stored at -80°C. Blood for the measurement of glucagon was pre-treated with aprotinine (370 kIU/ml; Roth GmbH, Karlsruhe, Germany). Plasma glucose was Depending on their distribution, data were subjected to analyses of variance (ANOVA; degrees of freedom corrected using the Greenhouse-Geisser procedure) or nonparametric tests. A P value <0.05 was considered significant.
Results

Experiment I: Intranasal ins-asp dose-dependently lowers blood glucose concentrations.
Baseline concentrations of all parameters were comparable between conditions (P>0.25). IN administration of ins-asp induced sustained dose-dependent decreases in plasma glucose concentrations within 45 min of treatment onset (P<0.0002 for Treatment × Time; Figure   1A ). In parallel, endogenous insulin concentrations decreased throughout the experiment (P<0.0001), with a trend towards even lower concentrations when ins-asp was administered (P=0.089 for Treatment; Figure 1B ). In accordance, ins-asp compared to placebo decreased serum C-peptide (P<0.002, Friedman tests; Figure 1C ). IN ins-asp treatment moreover increased GH concentrations and in the 420 IU condition attenuated the circadian decline in cortisol whereas a slight increase in glucagon was not significant (Table 2) (17) . However, the identification of a centrally mediated diazoxide effect on glucose production in that study was complicated by the clampinduced decrease in the physiological gradient between portal vein and systemic/cerebral artery insulin exposure, and by the fact that K + ATP -channels are also expressed in hepatic mitochondria (18) . Moreover, the regulation of hepatic glucose production is maintained in liver-transplanted patients (19) which does not speak for a superordinate relevance of the brain-liver axis in humans.
In our experiments, glucose concentrations started to decrease almost simultaneously with the rise in systemic ins-asp levels. However, we could not find any differences in glucose . Glucose-lowering effects of intracisternally administered insulin in dogs that appeared to depend on intact vagal nerve function could only be achieved with extremely high pharmacological doses of insulin (24) . Divergent findings in rodents and larger mammals like dogs and humans might be related to the fact that such larger organisms display 5-10 times smaller rates of endogenous glucose production than rodents, with the latter moreover exhibiting reduced hepatic glycogen reserves (22) . Given the greater physiological relevance access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
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